News

Phase III data for eye drug
Enlarge image

Clinical TrialsBelgium

Phase III data for eye drug

17.08.2012 - Belgian biopharmaceutical company ThromboGenics N.V. published encouraging data from two Phase III studies with its eye treatment experimental drug Ocriplasmin.

The studies published in New England Journal of Medicine (NEJM) including in total 652 patients found that the recombinant protein significantly resolved vitreomacular traction and closed macular holes compared to placebo in patients with vitreomacular adhesion (VMA). A health care practitioner, who treated patients in one of the studies said ocriplasmin could help a significant number of patients at an earlier point in their disease and improve their vision much more than surgery, which is the current standard of care.

"Results from the phase III programme with ocriplasmin are significant as they demonstrate the potential for using an enzymatic approach to resolve vitreomacular adhesion. This represents a real advance for patients living with vitreomacular adhesion who currently only have the option of surgery at a later stage of the disease," said Peter Stalmans, Department of Ophthalmology, University Hospitals, Leuven, Belgium. "The majority of patients who achieved resolution of their vitreomacular adhesion after a single intravitreal injection of ocriplasmin showed this positive outcome within the first seven days."

Ocriplasmin is a recombinant, truncated form of human plasmin that works by dissolving the proteins that link the vitreous to the macula. If approved, the drug, couldbecome the first pharmaceutical treatment for vitreomacular adhesion (VMA). Currently vitrectomy, or surgical removal of the vitreous from the eyeball, is the only available treatment for VMA. In patients with VMA, the vitreous adheres in an abnormally strong way to the retina, which can lead to traction on the retina, causing symptoms including impaired vision. Further unresolved traction may lead to the development of macular holes and central blindness.Thrombogenics developed the biologic and plans to market ocriplasmin on its own in the US. In a deal worth up to €300m in milestone payments and royalties Swiss drug maker Novartis’ subsidiary Alcon paid €75m up front in March to license the ex-US rights to the drug, which is currently under review by FDA and EMA.

http://www.european-biotechnology-news.com/news/news/2012-03/phase-iii-data-for-eye-drug.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014